Advertisement

Prevention Strategies for Brain Metastasis

  • Riccardo SoffiettiEmail author
  • Alessia Pellerino
  • Roberta Rudà
Chapter

Abstract

This chapter summarizes the state of art of the past and ongoing efforts in the setting of prevention of brain metastases. PCI has a definite role in the prevention of relapses in the brain of patients with SCLC, in particular for those who completely responded to chemotherapy and radiotherapy. Conversely, PCI is able to reduce the incidence of brain metastasis but does not improve overall survival in NSCLC.

The new frontier of prevention is represented by the use of molecular agents with activity on macrometastases, but an efficacy on micrometastases as well needs to be investigated in adequately designed prevention trials.

Keywords

PCI SCLC NSCLC Breast cancer Targeted agents 

References

  1. 1.
    Aur RJ, Hustu HO, Verzosa MS, Wood A, Simone JV. Comparison of two methods of preventing central nervous system leukemia. Blood. 1973;42(3):349–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep. 1981;65(9-10):811–4.PubMedGoogle Scholar
  3. 3.
    Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R. Cranial irradiation in cancer of the lung of all cell types. JAMA. 1981;245(5):469–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Arriagada R, Le Chevalier T, Borie F, Rivière A, Chomy P, Monnet I, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Kristjansen PE, Kristensen CA. The role of prophylactic cranial irradiation in the management of small cell lung cancer. Cancer Treat Rev. 1993;19(1):3–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001;1:5.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mamesaya N, Wakuda K, Omae K, Miyawaki E, Kotake M, Fujiwara T, et al. Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. Oncotarget. 2018;9(25):17664–74.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27(1):78–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee JS, Umsawasdi T, Lee YY, Barkley HT Jr, Murphy WK, Welch S, et al. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys. 1986;12(3):313–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson BE, Patronas N, Hayes W, Grayson J, Becker B, Gnepp D, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol. 1990;8(1):48–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Shaw EG, Su JQ, Eagan RT, Jett JR, Maksymiuk AW, Deigert FA. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol. 1994;12(11):2327–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol. 2011;22(5):1154–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Farooqi AS, Holliday EB, Allen PK, Wei X, Cox JD, Komaki R. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol. 2017;122(2):307–12.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64(2):226–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Lehman M, Gorayski P, Watson S, Edeling D, Jackson J, Whitty J. Patient preferences regarding prophylactic cranial irradiation: A discrete choice experiment. Radiother Oncol. 2016;121(2):225–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Harth S, Abo-Madyan Y, Zheng L, Siebenlist K, Herskind C, Wenz F, et al. Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Radiother Oncol. 2013;109(1):152–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Kundapur V, Ellchuk T, Ahmed S, Gondi V. Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation. Int J Radiat Oncol Biol Phys. 2015;91(4):781–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Nosaki K, Seto T, Shimokawa M, Takahashi T, Yamamoto N. Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy? Radiother Oncol. 2018;127(3):344–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, et al. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012;23(11):2919–24.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Krawczyk P, Duchnowska R, Nicoś M, Kowalski D, Wojas-Krawczyk K. Preventing central nervous system metastases in non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(11):1077–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Witlox WJA, Ramaekers BLT, Zindler JD, Eekers DBP, van Loon JGM, Hendriks LEL, et al. The prevention of brain metastases in non-small cell lung cancer by prophylactic cranial irradiation. Front Oncol. 2018;8:241:1–7.CrossRefGoogle Scholar
  26. 26.
    De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study. J Clin Oncol. 2018;36(23):2366–77.PubMedCrossRefGoogle Scholar
  27. 27.
    Xie SS, Li M, Zhou CC, Song XL, Wang CH. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014;9(7):e103431.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–86.PubMedCrossRefGoogle Scholar
  29. 29.
    Precival C, Landy M, Poole C, Mullaney L. The role of prophylactic cranial irradiation for non-small cell lung cancer. Anticancer Res. 2018;38(1):7–14.PubMedGoogle Scholar
  30. 30.
    Boggs DH, Robins HI, Langer CJ, Traynor AM, Berkowitz MJ, Mehta MP. Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014;15(6):433–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):24–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Palmieri D, Duchnowska R, Woditschka S, Hua E, Qian Y, Biernat W, et al. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res. 2014;20(10):2727–39.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Ilhan-Mutlu A, Osswald M, Liao Y, Gömmel M, Reck M, Miles D, et al. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther. 2016;15(4):702–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Trinh VA, Hwu WJ. Chemoprevention for brain metastases. Curr Oncol Rep. 2012;14(1):63–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406–14.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399–405.PubMedCrossRefGoogle Scholar
  37. 37.
    Li MX, He H, Ruan ZH, Zhu YX, Li RQ, He X, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer. 2017;17(1):245.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ma X, Zhu H, Guo H, Han A, Wang H, Jing W, et al. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget. 2016;7(49):81906–17.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Hochmair M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease. Target Oncol. 2018;13(3):269–85.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, et al. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758835918797589.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.PubMedCrossRefGoogle Scholar
  42. 42.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.PubMedCrossRefGoogle Scholar
  43. 43.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.PubMedCrossRefGoogle Scholar
  44. 44.
    Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018;118(1):38–42.PubMedCrossRefGoogle Scholar
  45. 45.
    Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2018;121:37–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35(9):177.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.PubMedCrossRefGoogle Scholar
  48. 48.
    Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase iii, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Pegram MD. Neratinib in ERBB2-positive brain metastases. JAMA Oncol. 2016;2(12):1541–3.PubMedCrossRefGoogle Scholar
  51. 51.
    Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(12):1557–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018;19(1):e20–32.PubMedCrossRefGoogle Scholar
  53. 53.
    Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: asco clinical practice guideline update. J Clin Oncol. 2018;36(27):2804–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014;25(10):1871–88.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3(8):1069–77.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B, et al. Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg. 2018;128(1):23–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Riccardo Soffietti
    • 1
    Email author
  • Alessia Pellerino
    • 1
  • Roberta Rudà
    • 1
  1. 1.Department of Neuro-OncologyUniversity and City of Health and Science Hospital TurinItaly

Personalised recommendations